Bausch Health Companies Inc. (TSE:BHC – Free Report) – Equities researchers at Zacks Research increased their FY2024 earnings per share estimates for shares of Bausch Health Companies in a report released on Tuesday, October 22nd. Zacks Research analyst R. Department now forecasts that the company will earn $4.98 per share for the year, up from their prior estimate of $4.88. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2024 earnings at $1.50 EPS, Q1 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.56 EPS, Q4 2025 earnings at $1.73 EPS, FY2025 earnings at $5.77 EPS, Q1 2026 earnings at $1.50 EPS and Q2 2026 earnings at $1.50 EPS.
A number of other equities research analysts have also issued reports on the company. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Raymond James upgraded Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 10th.
Bausch Health Companies Trading Down 0.3 %
Shares of BHC stock opened at C$11.18 on Thursday. Bausch Health Companies has a 52-week low of C$5.45 and a 52-week high of C$15.43. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19. The firm has a market capitalization of C$4.10 billion, a PE ratio of -6.39, a PEG ratio of 0.21 and a beta of 0.77. The stock has a fifty day simple moving average of C$9.50 and a two-hundred day simple moving average of C$9.95.
Bausch Health Companies (TSE:BHC – Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported C$1.22 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C$1.22. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The business had revenue of C$3.29 billion during the quarter, compared to analyst estimates of C$3.20 billion.
Insider Activity
In other news, Senior Officer Seana Lynne Carson sold 13,370 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. Company insiders own 11.28% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Articles
- Five stocks we like better than Bausch Health Companies
- Russell 2000 Index, How Investors Use it For Profitable Trading
- NextEra Energy’s Strong Quarter Catches Wall Street’s Eye
- 5 Top Rated Dividend Stocks to Consider
- Goldman’s Lost Decade Forecast: These 3 Growth Stocks Can Win
- 3 Tickers Leading a Meme Stock Revival
- WD-40 Company Gears Up for a Double-Digit Stock Advance
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.